Emicizumab
Emicizumab
Emicizumab (pronounced as em-ih-SIZ-uh-mab) is a monoclonal antibody designed for the treatment of hemophilia A. It is marketed under the brand name Hemlibra by Roche.
Etymology
The name "Emicizumab" is derived from the International Nonproprietary Names (INN), where "Emi-" refers to the target of the drug, "-ci-" indicates that it is a chimeric human/mouse antibody, "-zu-" denotes that it is humanized, and "-mab" is the suffix for monoclonal antibodies.
Usage
Emicizumab is used for the prevention and reduction of the frequency of bleeding episodes in patients with hemophilia A, a genetic disorder that prevents blood from clotting normally. It is especially beneficial for patients who have developed Factor VIII inhibitors.
Mechanism of Action
Emicizumab works by bridging activated Factor IX and Factor X, which are necessary for the coagulation cascade, thereby restoring the blood clotting process in patients with hemophilia A.
Related Terms
See Also
External links
- Medical encyclopedia article on Emicizumab
- Wikipedia's article - Emicizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski